Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 13;24(8):7186.
doi: 10.3390/ijms24087186.

Pathophysiology and Neuroimmune Interactions Underlying Parkinson's Disease and Traumatic Brain Injury

Affiliations
Review

Pathophysiology and Neuroimmune Interactions Underlying Parkinson's Disease and Traumatic Brain Injury

Alyssa Lillian et al. Int J Mol Sci. .

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder clinically defined by motor instability, bradykinesia, and resting tremors. The clinical symptomatology is seen alongside pathologic changes, most notably the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein and neuromelanin aggregates throughout numerous neural circuits. Traumatic brain injury (TBI) has been implicated as a risk factor for developing various neurodegenerative diseases, with the most compelling argument for the development of PD. Dopaminergic abnormalities, the accumulation of α-synuclein, and disruptions in neural homeostatic mechanisms, including but not limited to the release of pro-inflammatory mediators and the production of reactive oxygen species (ROS), are all present following TBI and are closely related to the pathologic changes seen in PD. Neuronal iron accumulation is discernable in degenerative and injured brain states, as is aquaporin-4 (APQ4). APQ4 is an essential mediator of synaptic plasticity in PD and regulates edematous states in the brain after TBI. Whether the cellular and parenchymal changes seen post-TBI directly cause neurodegenerative diseases such as PD is a point of considerable interest and debate; this review explores the vast array of neuroimmunological interactions and subsequent analogous changes that occur in TBI and PD. There is significant interest in exploring the validity of the relationship between TBI and PD, which is a focus of this review.

Keywords: Parkinson’s disease; S100A9; S100B; TBI; microglia; neurodegeneration; neuroinflammation; neuromelanin; oxidative stress; α-synuclein.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The timeline of inflammatory, immunological, cellular, and neural events occurs minutes to years following TBI.
Figure 2
Figure 2
The relationship between TBI and PD, with fundamental pathologic changes of both disorders in the center blue boxes. The dotted line and associated text represent a proposed mechanism by which TBI may induce PD development.

Similar articles

Cited by

References

    1. Cruz-Haces M., Tang J., Acosta G., Fernandez J., Shi R. Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases. Transl. Neurodegener. 2017;6:20. doi: 10.1186/s40035-017-0088-2. - DOI - PMC - PubMed
    1. Raza C., Anjum R., Shakeel N.U.A. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77–90. doi: 10.1016/j.lfs.2019.03.057. - DOI - PubMed
    1. Marras C., Beck J.C., Bower J.H., Roberts E., Ritz B., Ross G.W., Abbott R.D., Savica R., Van Den Eeden S.K., Willis A.W., et al. Prevalence of Parkinson’s disease across North America. NPJ Park. Dis. 2018;4:21. doi: 10.1038/s41531-018-0058-0. - DOI - PMC - PubMed
    1. Cacabelos R. Parkinson’s disease: From pathogenesis to pharmacogenomics. Int. J. Mol. Sci. 2017;18:551. doi: 10.3390/ijms18030551. - DOI - PMC - PubMed
    1. Delic V., Beck K.D., Pang K.C.H., Citron B.A. Biological links between traumatic brain injury and Parkinson’s disease. Acta Neuropathol. Commun. 2020;8:45. doi: 10.1186/s40478-020-00924-7. - DOI - PMC - PubMed

MeSH terms

Substances